report strong result re-affirmed guidanc metric except pharma
op profit revis expect medic guidanc re-affirmed better
expect like due cost reduct ppe think could upsid
est rebound elect procedur earlier management assumpt
recoveri second-half
impact thesi
increment posit follow earn management commentari
suggest underli busi perform well pharma
favor gener price dynam persist continu expect
gener program y/i tailwind said price trend could
transitori could deflationari pressur cost raw
materi subsid medic appear perform ahead plan regard
cost initi benefit although pace cost action
could slow due think could upsid est
rebound elect procedur favor management assumpt full
recoveri second-half
re-affirmed pharma revenue guidanc mid-singl digit growth lower op
profit guidanc mid-singl digit declin low-singl digit declin larg
expect accord management downward revis primarili attribut
expect impact nuclear busi well specialti although
much lesser extent estimate impact nuclear specialti neg
impact op profit guidanc note nuclear busi expect
particularli strong impact due higher margin profil high fix cost said
think strong perform gener program may help offset expect
neg impact
re-affirmed guidanc low-singl digit revenue growth low-doubl digit op profit
growth ahead expect believ cost initi particularli
around manufactur distribut higher normal sale ppe
enabl reaffirm segment guidanc declin elect procedur expect
particularli advers impact in-line expect note
benefit higher sale ppe expect reoccur
abl meet strong demand safeti stock deplet
guidanc re-affirmed except pharma op profit
re-affirmed element guidanc save pharma op profit mid-singl
digit percentag declin low-singl digit percentag declin encourag
provid explicit guidanc compani note
expect see full recoveri elect procedur second-half cite
difficulti get throughput level shortag ppe hesit patient
re-ent physician offic care set bit conserv
heard industri sourc estim full recoveri
pleas see page report import disclosur
would remain sidelin demonstr consist perform
medic segment plagu number issu howev
fundament pharma seem stabil improv management appear
execut stabil medic follow issu cordi medic solut
addit execut cost reduct streamlin initi increment
overhang relat opioid litig eas may elimin event
sign stabil medic
progress cost save program
reinvest growth
updat management strateg initi
growth
gross margin almost
oper margin
debt paydown
share repo
growth high-singl digit
due better expect growth
specialti and/or moder
expect impact
gross margin closer greater
expect benefit gener
perform medic
sg better expect due
oper leverag cost reduct
growth low-singl digit due
weaker expect contribut
medic and/or wors expect
impact
gross margin due weaker
expect gener profit
sg wors expect due less
oper leverag cost reduct
one three largest pharmaceut distribut compani
 oper billion pharmaceut market compani distribut
comprehens offer brand-nam gener pharmaceut over-the-count
healthcar product home healthcar suppli equip wide varieti
healthcar provid locat throughout includ acut care hospit health
system independ chain retail pharmaci mail-ord facil physician clinic
alternate-sit facil cardin oper today two report segment
pharmaceut medic cardin recent focus home health space
updat estim price
rais adj ep estimate lower adj ep estimate
note modestli lower estimate updat
estimate reflect management recoveri assumpt conserv initi
assumpt modestli rais pt base revis dcf
analysi impli share trade adj ep estimate
million except per-shar data
compani report cowen compani
changevariancetot good gross gross bp chang gener oper oper interest pre-tax pre-tax incom tax net incom continu net incom deal-rel discontinu operations- nm- non-recurring net incom weight averag continu ep deal-rel ep non-recurring ex-disc ep oper oper bp chang medic oper oper bp chang cowen
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per fiscal year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax incom tax incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag ep continu ep chang year-over-year oper incom continu continu year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax pre-tax incom tax net earn attribut non-controlling net incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag adj chang year-over-year oper incom continu continu cowen
million
compani report cowen compani
asset trade receiv merchandis prepaid expens asset held sale discontinu ops- current pp goodwil total current liabil current portion long-term account accru liabil busi held sale disc ops- current long-term defer tax redeem non-controlling stockhold equiti common retain common share cumul foreign currenc non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end june cowen
million
compani report cowen compani
income/ loss cumul effect chang accounting- earn /loss discontinu operations- earn cont op b/f effect chg flow oper activ depreci sale provis loss account charg reorg busi charges- sale invest businesses- employe stock defer incom invest impair chang oper asset liabil account merchandis prepaid expens assets- account oper net cash use /provid op activ disc ops- net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend common proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur year end june cowen
million
compani report cowen compani
flow oper activitiesnet cumul effect chang accounting- earn /loss discontinu earn cont op cumul effect chang adjust reconcil net earn net cash depreci sale asset loss debt sale carefus common stock- purchas in-process d- equiti provis defer incom tax provis bad debt chang fair valu conting consider oblig chang oper asset liabil net increas trade receiv increas increas net invest sales-typ leases- increas account oper item net net cash use /provid oper activ discontinu ops- net cash provid oper flow invest activ acquisition/divestitur subsidiari net cash acquir proce sale properti equip addit properti equip sale/ purchas market secur avail sale proce matur available-for-sal proce divestitur dispos held sale proce sale carefus common stock- net cash use /provid invest activ discontinu ops- net cash use invest flow financ activ payment conting net chang commerci paper short-term debt reduct long-term oblig net purchas non-controlling interests- proce interest rate swap terminations- proce long-term oblig net issuanc cost proce securit borrow payment premium debt extinguishment- proce issuanc common share tax benefit exercis stock purchas treasuri share net cash use /provid financ activ discontinu ops- net cash provid by/ use financ effect exchang rate chang cash equivalents- reclassfii asset held sale- net increas decreas chang fiscal year equival begin equival end fiscal year end june cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ
abil execut medic strategi cost reduct either wors better management
expect opioid litig expens greater expect manag abil
deploy capit effect
